Stockscreener 앱 받기
26.13
2.63%
0.67
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
Form 144 STOKE THERAPEUTICS For: 21 October By Investing.com - Investing.com Canada
A former affiliate plans to exercise options without cash and sell Stoke Therapeutics (STOK) shares. - Stock Titan
Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Has Average Target Price of $44.25 - MarketBeat
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Yahoo Finance
Form 4 Stoke Therapeutics Inc: Barry Ticho (CHIEF MEDICAL OFFICER) For: 1 October By Investing.com - Investing.com South Africa
Form 4 Stoke Therapeutics Inc: Jonathan Allan (GENERAL COUNSEL & CORP SEC) For: 2 October - Investing.com India
Stoke therapeutics general counsel Jonathan Allan sells $16,508 stock By Investing.com - Investing.com Nigeria
Form 4 Stoke Therapeutics Inc: Jonathan Allan (GENERAL COUNSEL & CORP SEC) For: 2 October - Investing.com Nigeria
Stoke therapeutics CMO Barry Ticho sells $27,493 in stock By Investing.com - Investing.com Canada
Stoke therapeutics CMO Barry Ticho sells $27,493 in stock - Investing.com
Stoke therapeutics general counsel Jonathan Allan sells $16,508 stock - Investing.com
Form 4 Stoke Therapeutics Inc: Jonathan Allan (GENERAL COUNSEL & CORP SEC) For: 2 October - Investing.com UK
Stoke therapeutics general counsel Jonathan Allan sells $16,508 stock By Investing.com - Investing.com UK
Stoke therapeutics CMO Barry Ticho sells $27,493 in stock By Investing.com - Investing.com UK
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting - Business Wire
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting - Business Wire
At $26.33 a share, Jonathan Allan sells 627 shares of Stoke Therapeutics (STOK). - Stock Titan
Officer Jonathan D. Allan proposes selling 627 shares of Stoke Therapeutics (STOK). - Stock Titan
Under a trading plan, Stoke Therapeutics (STOK) medical chief sells 1,051 shares. - Stock Titan
BVF Partners Reveals 5.6% Ownership Stake in Stoke Therapeutics Inc. (NASDAQ:STOK) - kalkinemedia.com
A passive stake at Stoke Therapeutics (STOK) includes 76,938 shares in a managed account. - Stock Titan
Form 4 Stoke Therapeutics Inc For: 26 September By Investing.com - Investing.com Nigeria
Form 4 Stoke Therapeutics Inc For: 26 September By Investing.com - Investing.com Australia
Stoke Therapeutics (STOK) grants director Alexander Cumbo options priced at $26.11 per share. - Stock Titan
Why Is Stoke Therapeutics, Inc. (STOK) Suddenly a Must-Watch Growth Stocks Name? - Kalkine Media
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Yahoo Finance
Stoke Therapeutics Stock Price Forecast. Should You Buy STOK? - StockInvest.us
Encoded Therapeutics Raises $275 Million to Advance Dravet Syndrome Gene Therapy - finance.biggo.com
Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence - Investing.com Nigeria
Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence - Investing.com Canada
Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence - Investing.com India
Stoke Therapeutics at Cantor conference: dravet data, cash runway By Investing.com - Investing.com India
Stoke Therapeutics at Cantor conference: dravet data, cash runway By Investing.com - Investing.com Canada
STOK: Phase III data for Dravet syndrome and strong OLE results position the pipeline for major milestones - TradingView
STOK: Phase III Dravet therapy shows durable 75%+ seizure reduction and functional gains in long-term data - TradingView
Stoke Therapeutics (STOK) Institutional Ownership 2026 $STOK - MarketBeat
Legal & General Group Plc Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. $STOK Shares Sold by Troluce Capital Advisors LLC - MarketBeat
Bank of New York Mellon Corp Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics and Biogen Present Long-Term Clinical Data tha - The National Law Review
Stoke Therapeutics CMO Barry Ticho Executes 5,545 Share Sales Under 10b5-1 Plan - Kalkine Media
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - manilatimes.net
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - Biogen
Biogen Inc. - Via Ritzau
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $170,065.15 in Stock - MarketBeat
Stoke Therapeutics (STOK) CMO sells 5,545 shares under pre-set plan - Stock Titan
Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation - Moomoo
The Manufacturers Life Insurance Company Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
12.15%
0.38%
자본화:
|
볼륨(24시간):